The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants

Protein Expression and Purification

Volumn 68, Issue 1, 2009, Pages 34-41

  Secchi, Massimiliano ^a   Xu, Qiang ^b   Lusso, Paolo ^a,c   Vangelista, Luca ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Osel Inc   (United States)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Anti HIV 1 microbicide; Lactobacilli; Mammalian cells; Protein folding; RANTES

Indexed keywords

RANTES;

ANIMAL; ARTICLE; CELL LINE; CHEMISTRY; CHO CELL; COMPARATIVE STUDY; CRICETULUS; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; HAMSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LACTOBACILLUS; METABOLISM; METHODOLOGY; MUTATION; PROTEIN FOLDING; PROTEIN MULTIMERIZATION; SECRETION;

ANIMALS; CELL LINE; CHEMOKINE CCL5; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DISCOVERY; HIV-1; HUMANS; LACTOBACILLUS; MUTATION; PROTEIN FOLDING; PROTEIN MULTIMERIZATION;

BACTERIA (MICROORGANISMS); EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LACTOBACILLUS; LACTOBACILLUS JENSENII; MAMMALIA; PROKARYOTA;

EID: 68349144589     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2009.06.018     Document Type: Article

References (35)

1. Seegers J.F. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol. 20 (2002) 508-515
2. Wells J.M., and Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6 (2008) 349-362
3. Klasse P.J., Shattock R., and Moore J.P. Antiretroviral drug-based microbicide to prevent HIV-1 sexual transmission. Annu. Rev. Med. 59 (2008) 455-471
4. Hladik F., Sakchalathorn P., Ballweber L., Lentz G., Fialkow M., Eschenbach D., and McElrath M.J. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26 (2007) 257-270
5. Cutler B., and Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8 (2008) 685-697
6. Fauci A.S. 25 years of HIV/AIDS science: reaching the poor with research advances. Cell 131 (2007) 429-432
7. Moscicki A.B. Vaginal microbicides: where are we and where are we going?. J. Infect. Chemother. 14 (2008) 337-341
8. Balzarini J., and Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 369 (2007) 787-797
9. Grant R.M., Hamer D., Hope T., Johnston R., Lange J., Lederman M.M., Lieberman J., Miller C.J., Moore J.P., Mosier D.E., Richman D.D., Schooley R.T., Springer M.S., Veazey R.S., and Wainberg M.A. Whither or wither microbicides?. Science 321 (2008) 532-534
10. Bolton M., van der Straten A., and Cohen C.R. Probiotics: potential to prevent HIV and sexually transmitted infections in women. Sex. Transm. Dis. 35 (2008) 214-225
11. Chang T.L., Chang C.H., Simpson D.A., Xu Q., Martin P.K., Lagenaur L.A., Schoolnik G.K., Ho D.D., Hillier S.L., Holodniy M., Lewicki J.A., and Lee P.P. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl. Acad. Sci. USA 100 (2003) 11672-11677
12. Pusch O., Boden D., Hannify S., Lee F., Tucker L.D., Boyd M.R., Wells J.M., and Ramratnam B. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J. Acquir. Immune Defic. Syndr. 40 (2005) 512-520
13. Chancey C.J., Khanna K.V., Seegers J.F., Zhang G.W., Hildreth J., Langan A., and Markham R.B. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J. Immunol. 176 (2006) 5627-5636
14. Pusch O., Kalyanaraman R., Tucker L.D., Wells J.M., Ramratnam B., and Boden D. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 20 (2006) 1917-1922
15. Liu X., Lagenaur L.A., Simpson D.A., Essenmacher K.P., Frazier-Parker C.L., Liu Y., Tsai D., Rao S.S., Hamer D.H., Parks T.P., Lee P.P., and Xu Q. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50 (2006) 3250-3259
16. Liu J.J., Reid G., Jiang Y., Turner M.S., and Tsai C.C. Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell. Microbiol. 9 (2007) 120-130
17. Liu X., Lagenaur L.A., Lee P.P., and Xu Q. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl. Environ. Microbiol. 74 (2008) 4626-4635
18. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., and Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270 (1995) 1811-1815
19. Vangelista L., Secchi M., and Lusso P. Rational design of novel HIV-1 entry inhibitors by RANTES engineering. Vaccine 26 (2008) 3008-3015
20. Lederman M.M., Veazey R.S., Offord R., Mosier D.E., Dufour J., Mefford M., Piatak Jr. M., Lifson J.D., Salkowitz J.R., Rodriguez B., Blauvelt A., and Hartley O. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306 (2004) 485-487
21. Magistrelli G., Gueneau F., Muslmani M., Ravn U., Kosco-Vilbois M., and Fischer N. Chemokines derived from soluble fusion proteins expressed in Escherichia coli are biologically active. Biochem. Biophys. Res. Commun. 334 (2005) 370-375
22. Cho H.J., Lee Y., Chang R.S., Hahm M.S., Kim M.K., Kim Y.B., and Oh Y.K. Maltose binding protein facilitates high-level expression and functional purification of the chemokines RANTES and SDF-1alpha from Escherichia coli. Protein Expr. Purif. 60 (2008) 37-45
23. Polo S., Nardese V., De Santis C., Arcelloni C., Paroni R., Sironi F., Verani A., Rizzi M., Bolognesi M., and Lusso P. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. Eur. J. Immunol. 30 (2000) 3190-3198
24. Comuzzi B., Arcelloni C., Polo S., Nardese V., Lusso P., and Paroni R. Multi-step purification strategy for RANTES wild-type and mutated analogues expressed in a baculovirus system. J. Chromatogr. B Biomed. Sci. Appl. 737 (2000) 47-54
25. Lusso P., Cocchi F., Balotta C., Markham P.D., Louie A., Farci P., Pal R., Gallo R.C., and Reitz Jr. M.S. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 69 (1995) 3712-3720
26. Drider D., Fimland G., Héchard Y., McMullen L.M., and Prévost H. The continuing story of class IIa bacteriocins. Microbiol. Mol. Biol. Rev. 70 (2006) 564-582
27. Heras B., Kurz M., Jarrott R., Shouldice S.R., Frei P., Robin G., Cemazar M., Thöny-Meyer L., Glockshuber R., and Martin J.L. Staphylococcus aureus DsbA does not have a destabilizing disulfide. A new paradigm for bacterial oxidative folding. J. Biol. Chem. 283 (2008) 4261-4271
28. Straume D., Axelsson L., Nes I.F., and Diep D.B. Improved expression and purification of the correctly folded response regulator PlnC from lactobacilli. J. Microbiol. Methods 67 (2006) 193-201
29. Skelton N.J., Aspiras F., Ogez J., and Schall T.J. Proton NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biochemistry 34 (1995) 5329-5342
30. Chung C.W., Cooke R.M., Proudfoot A.E., and Wells T.N. The threedimensional solution structure of RANTES. Biochemistry 34 (1995) 9307-9314
31. Czaplewski L.G., McKeating J., Craven C.J., Higgins L.D., Appay V., Brown A., Dudgeon T., Howard L.A., Meyers T., Owen J., Palan S.R., Tan P., Wilson G., Woods N.R., Heyworth C.M., Lord B.I., Brotherton D., Christison R., Craig S., Cribbes S., Edwards R.M., Evans S.J., Gilbert R., Morgan P., Randle E., Schofield N., Varley P.G., Fisher J., Waltho J.P., and Hunter M.G. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J. Biol. Chem. 274 (1999) 16077-16084
32. Vangelista L., Cesco-Gaspere M., Lamba D., and Burrone O. Efficient folding of the Fc epsilon RI alpha-chain membrane-proximal domain D2 depends on the presence of the N-terminal domain D1. J. Mol. Biol. 322 (2002) 815-825
33. Maekawa A., Schmidt B., Fazekas de St Groth B., Sanejouand Y.H., and Hogg P.J. Evidence for a domain-swapped CD4 dimer as the coreceptor for binding to class II MHC. J. Immunol. 176 (2006) 6873-6878
34. Brandner B., Rek A., Diedrichs-Möhring M., Wildner G., and Kungl A.J. Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists. Protein Eng. Des. Sel. 22 (2009) 367-373
35. Sevastsyanovich S., Alfasi S., and Cole J. Recombinant protein production: a comparative view on host physiology. N. Biotechnol. 25 (2009) 175-180